Yong Lu

ORCID: 0000-0003-0077-0040
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Multiple Myeloma Research and Treatments
  • Viral Infectious Diseases and Gene Expression in Insects
  • Immune cells in cancer
  • T-cell and B-cell Immunology
  • RNA Interference and Gene Delivery
  • Virus-based gene therapy research
  • Chemokine receptors and signaling
  • Bone health and treatments
  • Cancer Cells and Metastasis
  • Cancer Research and Treatments
  • Hepatitis B Virus Studies
  • SARS-CoV-2 and COVID-19 Research
  • vaccines and immunoinformatics approaches
  • Bone Metabolism and Diseases
  • Vaccine Coverage and Hesitancy
  • Hepatitis C virus research
  • Peptidase Inhibition and Analysis
  • Hepatitis Viruses Studies and Epidemiology
  • Immune Response and Inflammation
  • Nanowire Synthesis and Applications
  • Cell Adhesion Molecules Research

Houston Methodist
2023-2025

Weill Cornell Medicine
2024

Methodist Hospital
2024

Cornell University
2024

Methodist Hospital
2023

Wake Forest University
2018-2022

Atrium Health Wake Forest Baptist
2020-2022

Wake Forest Baptist Comprehensive Cancer Center
2020-2022

The University of Texas MD Anderson Cancer Center
2010-2021

Cleveland Clinic Lerner College of Medicine
2014-2018

Abstract Mounting evidence suggests that the tumor microenvironment is profoundly immunosuppressive. Thus, mitigating immunosuppression crucial for inducing sustained antitumor immunity. Whereas previous studies involved intratumoral injection, we report here an inhalable nanoparticle-immunotherapy system targeting pulmonary antigen presenting cells (APCs) to enhance anticancer immunity against lung metastases. Inhalation of phosphatidylserine coated liposome loaded with STING agonist cyclic...

10.1038/s41467-019-13094-5 article EN cc-by Nature Communications 2019-11-08

Tumor-infiltrating myeloid cells are the most abundant leukocyte population within tumors. Molecular cues from tumor microenvironment promote differentiation of immature toward an immunosuppressive phenotype. However, in situ dynamics transcriptional reprogramming underlying this process poorly understood. Therefore, we applied single cell RNA-seq (scRNA-seq) to computationally investigate cellular composition and adjacent normal tissues 4 early-stage non-small lung cancer (NSCLC) patients....

10.1002/cam4.2113 article EN cc-by Cancer Medicine 2019-04-29

Significance Our laboratory has identified a critical role of IL-9 in promoting endogenous tumor-specific cytotoxic T lymphocyte response. In this study, we found that differentiation CD8 + cells under helper 9-polarizing conditions induces the development an IL-9–producing less cytolytic IL-9–skewed (Tc9) cell subset. Noticeably, adoptive transfer tumor-reactive Tc9 elicited greater antitumor responses against large established tumors than classic type-I are used clinical protocols....

10.1073/pnas.1317431111 article EN Proceedings of the National Academy of Sciences 2014-01-27

Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first and rate-limiting step in converting tryptophan to kynurenine. Chimeric antigen receptor (CAR) T cells are with recombinant receptors targeting tumor-associated antigens. The Food Drug Administration has approved CAR that target CD19 for treatment of advanced B cell leukemia lymphoma. However, therapy solid tumors been hampered by multiple obstacles. Preclinical clinical studies suggest combinatorial immune checkpoint blockade IDO1...

10.1186/s13045-018-0600-x article EN cc-by Journal of Hematology & Oncology 2018-04-23

Abstract IL-9-producing CD4 + (Th9) cells are a subset of T-helper that endowed with powerful antitumor capacity. Both IL-4 and TGF-β have been reported to be indispensable for Th9 cell-priming differentiation. Here we show, by contrast, cell development can occur in the absence signaling. When was replaced IL-1β, combination IL-1β efficiently promoted T (Th9 IL-4+IL-1β ). IL-4+ phenotypically distinct compared classic IL-4+TGF-β ) other Th cells, enriched IL-1 NF-κB gene signatures....

10.1038/s41467-019-09401-9 article EN cc-by Nature Communications 2019-03-26

Malignant pleural effusion (MPE) is indicative of terminal malignancy with a uniformly fatal prognosis. Often, two distinct compartments tumour microenvironment, the and disseminated tumours, co-exist in cavity, presenting major challenge for therapeutic interventions drug delivery. Clinical evidence suggests that MPE comprises abundant tumour-associated myeloid cells tumour-promoting phenotype, impairing antitumour immunity. Here we developed liposomal nanoparticle loaded cyclic...

10.1038/s41565-021-01032-w article EN cc-by Nature Nanotechnology 2021-12-16

CAR-T cell therapy is effective for hematologic malignancies. However, considerable numbers of patients relapse after the treatment, partially due to poor expansion and limited persistence cells in vivo. Here, we demonstrate that human polarized expanded under a Th9-culture condition (T9 CAR-T) have an enhanced antitumor activity against established tumors. Compared IL2-polarized (T1) cells, T9 secrete IL9 but little IFN-γ, express central memory phenotype lower levels exhaustion markers,...

10.1038/s41467-020-19672-2 article EN cc-by Nature Communications 2020-11-19

Cancer stem-like cells (CSLCs) acquire enhanced immune checkpoint responses to evade cell killing and promote tumor progression. Here we showed that signal regulatory protein γ (SIRPγ) determined CSLC properties evasiveness in a small population of lung adenocarcinoma (LUAD) cancer cells. A SIRPγhi displayed transmitted the escape through sustaining CD47 expression both SIRPγlo/- SIRPγ bridged MST1 PP2A facilitate dephosphorylation, resulting Hippo/YAP activation leading cytokine release by...

10.1172/jci141797 article EN cc-by Journal of Clinical Investigation 2022-02-28

p38 mitogen-activated protein kinase (MAPK), which is constitutively activated in human myeloma, has been implicated bone destruction by this cancer, but the processes it recruits are obscure. In study, we show that activity myeloma inhibits osteoblast differentiation and formation, also enhances osteoclast maturation resorption. regulated expression secretion of Wnt pathway antagonist DKK-1 monocyte chemoattractant MCP-1. Attenuating p38, DKK-1, or MCP-1 were each sufficient to reduce...

10.1158/0008-5472.can-12-2664 article EN Cancer Research 2012-10-13

p38 MAPK signaling controls cell growth, proliferation and the cycle under stress conditions. However, function of activation in tumor metastasis is still not well understood. We report that breast cancer cells inhibits but does substantially modulate primary growth. Stable knockdown suppressed NF-κB p65 activation, inhibiting miR-365 expression resulting increased IL-6 secretion. The inhibitory effect on was mediated by suppression mesenchymal stem (MSC) migration to sites metastasis, where...

10.1002/ijc.28958 article EN International Journal of Cancer 2014-05-08

Multiple myeloma (MM) remains an incurable cancer characterized by accumulation of malignant plasma cells in the bone marrow (BM). The mechanism underlying MM homing to BM is poorly elucidated.The clinical significance migration inhibitory factor (MIF) expression was examined analyzing six independent gene profile databases primary using Student's t test and Kaplan-Meier test. Enzyme-linked immunosorbent assay used examine MIF expression. In vivo bioluminescent imaging determine cell...

10.1093/jnci/djw131 article EN JNCI Journal of the National Cancer Institute 2016-07-05

Th17 cells play a critical role in both tissue homeostasis and inflammation during clearance of infections as well autoimmune inflammatory disorders. Despite numerous efforts to distinguish the homeostatic roles cells, mechanism underlying divergent functions remains poorly understood. In this study, we demonstrate that involved colitis those activated colitogenic infection are distinguishable populations characterized by their differential responses pharmacological molecule, clofazimine...

10.1084/jem.20221911 article EN cc-by-nc-sa The Journal of Experimental Medicine 2023-06-27
Coming Soon ...